$CPXX.new volume breakout candles Pr. Nasdaq Cm $
Post# of 22756
Posted On: 02/21/2016 2:35:12 PM
$CPXX.new volume breakout candles Pr.
Nasdaq Cm $2.18
CPXX: Celator is ready to Commercialize VYXEOS
™Zacks Small Cap Research (Wed, Feb 17)
Website
Shares Outstanding5 34.55M
Float: 22.85M
% Held by Insiders: 37.58%
% Held by Institutions: 8.70%
Shares Short (as of Jan 29, 2016)31.08M
Short Ratio (as of Jan 29, 2016): 5.21
Short % of Float (as of Jan 29, 2016): 4.18%
Shares Short (prior month): 788.32K
Headlines
Company Profile - Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The companys product pipeline includes CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidate is CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for vitro and vivo studies. The company was founded in 1999 and is headquartered in Ewing, New Jersey.
Nasdaq Cm $2.18
CPXX: Celator is ready to Commercialize VYXEOS
™Zacks Small Cap Research (Wed, Feb 17)
Website
Shares Outstanding5 34.55M
Float: 22.85M
% Held by Insiders: 37.58%
% Held by Institutions: 8.70%
Shares Short (as of Jan 29, 2016)31.08M
Short Ratio (as of Jan 29, 2016): 5.21
Short % of Float (as of Jan 29, 2016): 4.18%
Shares Short (prior month): 788.32K
Headlines
Company Profile - Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The companys product pipeline includes CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidate is CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for vitro and vivo studies. The company was founded in 1999 and is headquartered in Ewing, New Jersey.
(0)
(0)Scroll down for more posts ▼